PapersPMID:36181264
The effect of green cardamom on blood pressure and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized clinical trials.
- findings
- 4
- compound
- 1
- endpoints
- 4
- no difference found
- 1
- Study, every finding
- meta-analysis
- Population, every finding
- patients with metabolic syndrome and related disorders; random-effects pooling of randomized clinical trials
What moved
How to read these marks →“The findings indicated that green cardamom significantly decreased diastolic blood pressure (WMD: -0.91 mmHg, 95%CI; -1.19, -0.62), high-sensitivity C-reactive protein (WMD: -1.21 mg/L, 95%CI; -2.18, -0.24), interleukin 6 levels (WMD: -2.41 ng/L, 95%CI; -4.35, -0.47).”
- Decreases C-reactive protein concentration
very limited
- Effect
- −1.21 mean difference, 95% CI −2.18 to −0.24
- Decreases diastolic blood pressure
very limited
- Effect
- −0.91 mean difference, 95% CI −1.19 to −0.62
- Decreases interleukin-6 concentration
very limited
- Effect
- −2.41 mean difference, 95% CI −4.35 to −0.47
What did not
- No detected effect on systolic blood pressure
very limited
“However, cardamom supplementation did not significantly affect systolic blood pressure.”
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Patients with metabolic syndrome and related disorders in randomized clinical trials of green cardamom (Elettaria cardamomum seeds); eight reports, 595 patients pooled (abstract only)
- Participants
- 595
- Comparator
- not stated in the paper
- Duration
- not reported
- Endpoints measured
- 4